Applied physicists in the Harvard John A. Paulson School of Engineering and Applied Sciences (SEAS) have discovered a new way to generate ultra-precise, evenly spaced "combs" of laser light on a ...

A live webcast will be accessible through the Company’s website at www.verupharma.com. Following the event, an archived webcast will be available on the Veru website.

Two new drug applications (NDA) for ulixacaltamide in essential tremor (ET) and for relutrigine in SCN2A and SCN8A developmental and epileptic ...

The trial is expected to provide early pharmacodynamic data to inform dose selection.

Krystal is leveraging a validated, redosable platform with high margins, profitability, and multiple blockbuster catalysts in CF and NK. Read why KRYS is a Buy.

Bristol Myers Squibb said the U.S. Food and Drug Administration has granted priority review to its application seeking approval of its iberdomide drug candidate in certain patients with the blood ...

Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) for iberdomide combined with standard treatment (daratumumab ...

Presentation will highlight lead clinical candidate FMP374, a novel dual-acting NMDAR modulator advancing toward IND-enabling ...

A near-infrared light beam appears harmless, as it is a low-frequency type of light that does not have a dramatic effect but ...

Warner Bros. was once developing a live-action/CGI hybrid Marvin the Martian film that was rumored to star Mike Myers. You ...

Neurocrine Biosciences, Inc. leverages a strong cash position and a neuropsychiatry pipeline to drive long-term commercial ...

Dewpoint Therapeutics Inc. has selected a development candidate in its MYC program. The first-in-class small molecule is designed to disrupt MYC-driven oncogenic transcription by modulating the ...